Key Dates

Related Announcements

RFA-CA-22-045 - NCI Outstanding Investigator Award (R35 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the section Eligible Individuals (Program Director/Principal Investigator) in Section III. Eligibility Information, Part 2. Full Text of Announcement, in RFA-CA-22-045, NCI Outstanding Investigator Award (R35 Clinical Trial Optional).
 

The following section of RFA-CA-22-045 has been corrected:

Part 2. Full Text of Announcement, Section III. Eligibility Information

Eligible Individuals (Program Director/Principal Investigator)
 

Currently reads:

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

 
Corrected to read (by deletion of the second paragraph above):

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

All other aspects of RFA-CA-22-045 remain unchanged.

Inquiries

Please direct all inquiries to:

Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: siemonc@mail.nih.gov